MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

(2015) M. P. Morelli et al.   ANNALS OF ONCOLOGY

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

(2015) S. Arena et al.   CLINICAL CANCER RESEARCH

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

(2015) J. D. Kearns et al.   MOLECULAR CANCER THERAPEUTICS

The genomic landscape of response to EGFR blockade in colorectal cancer

(2015) Andrea Bertotti et al.   NATURE

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

(2015) Lecia V. Sequist et al.   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

(2015) R. Dienstmann et al.   Cancer Discovery

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab

(2015) Mareike Voigt et al.   NEOPLASIA

O-0011 * FREQUENCY OF S492R MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR: ANALYSIS OF PLASMA DNA FROM METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH PANITUMUMAB OR CETUXIMAB MONOTHERAPY

(2014) K. Newhall et al.   ANNALS OF ONCOLOGY

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy

(2014) Don L. Gibbons et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2014) S. Misale et al.   Science Translational Medicine

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution

(2014) S. Misale et al.   Cancer Discovery

Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing

(2014) Sumitra Mohan et al.   PLoS Genetics

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

(2013) S. Soverini et al.   BLOOD

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

(2013) G. M. Blumenthal et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

(2013) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2013) Alberto Bardelli et al.   Cancer Discovery

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

(2012) J. S. Khorashad et al.   BLOOD

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

(2012) Sandra Misale et al.   NATURE

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

(2012) Luis A. Diaz Jr et al.   NATURE

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

(2012) Clara Montagut et al.   NATURE MEDICINE

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

(2011) K. Yonesaka et al.   Science Translational Medicine

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic MABS C225 and 425

(2010) Vishal Kamat et al.   CANCER BIOLOGY & THERAPY

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imatinib and beyond—exploring the full potential of targeted therapy for CML

(2009) Alfonso Quintás-Cardama et al.   Nature Reviews Clinical Oncology

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

(2009) T. Ben-Kasus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

(2008) F. Di Nicolantonio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA